Journal article
Modern prevalence of dysbetalipoproteinemia (Fredrickson-Levy-Lees type III hyperlipoproteinem)
Archives of medical science, v 16(5), pp 993-1003
2020
PMID: 32863987
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Introduction: Dysbetalipoproteinaemia (HLP3) is a disorder characterized by excess cholesterol-enriched, triglyceride-rich lipoprotein remnants in genetically predisposed individuals that powerfully promote premature cardiovascular disease if untreated. The current prevalence of HLP3 is largely unknown.
Material and methods: We performed cross-sectional analysis of 128,485 U.S. adults from the Very Large Database of Lipids (VLDbL), using four algorithms to diagnose HLP3 employing three Vertical Auto Profile ultracentrifugation (UC) criteria and a previously described apolipoprotein B (apoB) method. We evaluated 4,926 participants from the 2011-2014 National Health and Nutrition Examination Survey (NHANES) with the apoB method. We examined demographic and lipid characteristics stratified by presence of HLP3 and evaluated lipid characteristics in those with HLP3 phenotype discordance and concordance as determined by apoB and originally defined UC criteria 1.
Results: In U.S. adults in VLDbL and NHANES, a 1.7-2.0% prevalence is observed for HLP3 with the novel apoB method as compared to 0.2-0.8% prevalence in VLDbL via UC criteria 1-3. Participants who were both apoB and UC criteria HLP3 positive had higher remnant particles as well as more elevated triglyceride/apoB and total cholesterol/apoB ratios (all p < 0.001) than those who were apoB method positive and UC criteria 1 negative.
Conclusions: HLP3 may be more prevalent than historically and clinically appreciated. The apoB method increases HLP3 identification via inclusion of milder phenotypes. Further work should evaluate the clinical implications of HLP3 diagnosis at various lipid algorithm cut-points to evaluate the ideal standard in the modern era.
Metrics
Details
- Title
- Modern prevalence of dysbetalipoproteinemia (Fredrickson-Levy-Lees type III hyperlipoproteinem)
- Creators
- Vincent A. Pallazola - Johns Hopkins UniversityVasanth Sathiyakumar - Johns Hopkins UniversityJihwan Park - Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USARachit M. Vakil - Johns Hopkins UniversityPeter P. Toth - Johns Hopkins UniversityMariana Lazo-Elizondo - Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USAEmily Brown - Johns Hopkins UniversityRenato Quispe - Johns Hopkins UniversityEliseo Guallar - Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USAMaciej Banach - University of Zielona GóraRoger S. Blumenthal - Johns Hopkins UniversitySteven R. Jones - Johns Hopkins UniversityDavid Marais - University of Cape TownDaniel Soffer - College Station Medical CenterAllan D. Sniderman - McGill UniversitySeth S. Martin - Johns Hopkins University
- Publication Details
- Archives of medical science, v 16(5), pp 993-1003
- Publisher
- Termedia Publishing House Ltd
- Number of pages
- 11
- Grant note
- CASCADE FH Maryland Innovation Initiative Google; Google Incorporated Nokia; Nokia Corporation Apple David and June Trone Family Foundation American Heart Association Stanford MedX PJ Schafer Cardiovascular Research Fund iHealth Aetna Foundation
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Urban Health Collaborative
- Web of Science ID
- WOS:000559104100003
- Scopus ID
- 2-s2.0-85090918181
- Other Identifier
- 991020550347804721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Cardiac & Cardiovascular Systems